Processa officer buys 2,106 shares in open market

Processa Pharmaceuticals, Inc. executive Patrick Lin, Chief Business-Strategy Officer, bought additional common stock in the company.

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. executive Patrick Lin, Chief Business-Strategy Officer, bought additional common stock in the company. On June 30, 2026, he made an open-market purchase of 2,106 shares at $1.93 per share.

After this transaction, Lin directly holds 13,113 common shares. The filing also lists an indirect holding of 1,740 shares registered under the Lin Family Trust dated February 4, 2024, giving investors a clearer view of both his direct and trust-related ownership.

Insights

Equity ownership analyst

Small open-market insider buy modestly increases direct holdings.

Patrick Lin, an officer of Processa Pharmaceuticals, executed an open-market purchase of 2,106 common shares at $1.93 per share. Open-market buys generally reflect a deliberate decision to increase exposure at prevailing prices.

Following the trade, Lin’s direct stake rises to 13,113 shares, with an additional 1,740 shares held indirectly via the Lin Family Trust. The scale visible here appears modest, suggesting a routine portfolio adjustment rather than a transformative change in insider ownership.

Insider Trade Summary

Net Buyer: 2,106 shares

Net Buy 2 txns

Insider Lin Patrick

Role Chief Business - Strategy Off

Bought 2,106 shs ($4K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,106	$1.93	$4K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 13,113 shares (Direct); Common Stock — 1,740 shares (Indirect, Lin Family Trust Feb 4, 2024)

Key Figures

Shares purchased: 2,106 shares Purchase price: $1.93 per share Direct holdings after transaction: 13,113 shares +2 more

5 metrics

Shares purchased 2,106 shares Open-market purchase on June 30, 2026

Purchase price $1.93 per share Price for June 30, 2026 open-market buy

Direct holdings after transaction 13,113 shares Common stock directly owned by Patrick Lin post-buy

Indirect trust holdings 1,740 shares Common stock held via Lin Family Trust Feb 4, 2024

Net buy-sell shares 2,106 shares Net-buy direction for this Form 4 period

Key Terms

open-market purchase, indirect holding, Lin Family Trust Feb 4, 2024, Form 4

4 terms

open-market purchase financial

"he made an open-market purchase of 2,106 shares at $1.93 per share"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect holding financial

"The filing also lists an indirect holding of 1,740 shares registered under the Lin Family Trust"

Lin Family Trust Feb 4, 2024 financial

"indirect holding of 1,740 shares registered under the Lin Family Trust dated February 4, 2024"

Form 4 regulatory

"as shown in the Form 4. This filing updates investors"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Patrick Lin report for Processa Pharmaceuticals (PCSA)?

Patrick Lin reported buying Processa Pharmaceuticals common stock in the open market. He acquired 2,106 shares on June 30, 2026, as shown in the Form 4. This filing updates investors on his latest personal investment activity in the company’s shares.

How many Processa Pharmaceuticals (PCSA) shares did Patrick Lin buy and at what price?

Patrick Lin bought 2,106 shares of Processa Pharmaceuticals common stock at a price of $1.93 per share. This was an open-market purchase dated June 30, 2026, and it increased his directly held position in the company.

What are Patrick Lin’s total direct Processa Pharmaceuticals (PCSA) holdings after this Form 4?

After the June 30, 2026 transaction, Patrick Lin directly owns 13,113 shares of Processa Pharmaceuticals common stock. This total reflects his existing position plus the newly purchased 2,106 shares, giving investors a clearer picture of his direct ownership stake.

What indirect holdings in Processa Pharmaceuticals (PCSA) does the Lin Family Trust report?

The Form 4 lists 1,740 shares of Processa Pharmaceuticals common stock as indirectly owned through the Lin Family Trust dated February 4, 2024. This entry describes an existing trust holding, separate from Patrick Lin’s directly owned 13,113 shares after the recent purchase.

Does the Form 4 for Processa Pharmaceuticals (PCSA) show any insider share sales?

The Form 4 indicates no reported insider sales for Patrick Lin. It records one open-market purchase of 2,106 common shares and a separate holding entry for 1,740 indirectly owned shares, resulting in a net-buy direction for this filing period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Patrick

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business - Strategy Off

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		P		2,106	A	$1.93	13,113	D
Common Stock								1,740	I	Lin Family Trust Feb 4, 2024

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)